JCR Pharmaceuticals Announces Gain on Deferred Income Taxes

JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ) has provided an update.

JCR Pharmaceuticals Co., Ltd. has announced a recognition of gain on deferred income taxes for the fiscal year ended March 31, 2025, resulting in a corporate tax adjustment profit of 1,771 million yen. This adjustment reflects the company’s performance trends and careful review of deferred tax assets’ recoverability, impacting the consolidated financial results positively and demonstrating JCR’s strategic financial management.

The most recent analyst rating on (JP:4552) stock is a Buy with a Yen700.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.

More about JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceuticals company focused on expanding possibilities for people with rare and genetic diseases worldwide. With a 50-year legacy in Japan, the company is expanding its global presence in the US, Europe, and Latin America. JCR is dedicated to improving patients’ lives through scientific expertise and unique technologies, developing next-generation therapies. Its approved products in Japan include treatments for growth disorder, MPS II, Fabry disease, acute graft-versus-host disease, and renal anemia, while investigational products target various rare diseases.

Average Trading Volume: 652,898

Technical Sentiment Signal: Strong Sell

Current Market Cap: Yen58.29B

For detailed information about 4552 stock, go to TipRanks’ Stock Analysis page.